ICICI Bank Limited Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? ICICI Bank Limited Common Stock trades at $28.37 (market cap $101.96B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: ICICI Bank Limited Common Stock is far larger — about 68.9× uniQure N.V. Ordinary Shares's market cap, and ICICI Bank Limited Common Stock pays a 0.88% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold ICICI Bank Limited Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IBN | QURE | |
|---|---|---|
Market Cap | $101.96B | $1.48B |
Volume | 5,301,480 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $32.94 | $70.59 |
52-Week Low | $25.20 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.90T | $728.62M |
Dividend Yield | 0.88% | — |
Signals from Pluang's Aura AI — not financial advice
IBN trades at $28.54, up 1.75% today, showing strong momentum with recent earnings beats in Q1 and Q2 2026. The stock maintains robust fundamentals including a 24.8% net income margin and 15.8% ROE, supported by $2.05T revenue in 2025. Technical indicators show bearish signals despite unanimous analyst buy ratings, with RSI suggesting potential overbought conditions near current levels.
The outlook remains positive given strong profitability metrics and analyst consensus, but technical weakness and high valuation multiples (P/E 17.85, P/S 4.43) present near-term risks. Investors should monitor Q3 2026 earnings results against expectations of $0.40 EPS for continued fundamental confirmation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ICICI Bank is an Indian financial services company providing banking, lending, cards, insurance, and investment products. It serves retail, business, and corporate customers.
Read more on IBN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →